RGS5 and neoplasm: It has been shown that Listeria monocytogenes (Lm)-based vaccine targeting RGS5 exhibits potent anti-tumor effects by recruiting functional type-1-associated T cells and reducing tumor blood vessel rates in syngeneic mouse models of CRC.